IL123142A - The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus - Google Patents

The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus

Info

Publication number
IL123142A
IL123142A IL12314296A IL12314296A IL123142A IL 123142 A IL123142 A IL 123142A IL 12314296 A IL12314296 A IL 12314296A IL 12314296 A IL12314296 A IL 12314296A IL 123142 A IL123142 A IL 123142A
Authority
IL
Israel
Prior art keywords
tinnitus
use according
adamantane derivatives
atoms
adamantane
Prior art date
Application number
IL12314296A
Other languages
English (en)
Hebrew (he)
Other versions
IL123142A0 (en
Original Assignee
Tinnitus Forschungs Und Entwic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tinnitus Forschungs Und Entwic filed Critical Tinnitus Forschungs Und Entwic
Publication of IL123142A0 publication Critical patent/IL123142A0/xx
Publication of IL123142A publication Critical patent/IL123142A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12314296A 1995-08-02 1996-07-31 The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus IL123142A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
PCT/EP1996/003360 WO1997004762A1 (de) 1995-08-02 1996-07-31 Verwendung von adamantan-derivaten zur behandlung von erkrankungen des innenohrs

Publications (2)

Publication Number Publication Date
IL123142A0 IL123142A0 (en) 1998-09-24
IL123142A true IL123142A (en) 2001-10-31

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12314296A IL123142A (en) 1995-08-02 1996-07-31 The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus

Country Status (14)

Country Link
US (1) US6066652A (es)
EP (2) EP0759295B1 (es)
JP (1) JP3568039B2 (es)
KR (1) KR100393296B1 (es)
CN (1) CN1142775C (es)
AT (1) ATE163545T1 (es)
AU (1) AU719018B2 (es)
BR (1) BR9609950A (es)
DE (3) DE19528388A1 (es)
DK (1) DK0759295T3 (es)
ES (1) ES2116801T3 (es)
IL (1) IL123142A (es)
PL (1) PL324795A1 (es)
WO (1) WO1997004762A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7132406B2 (en) * 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
EP1814532B1 (en) 1999-05-27 2012-01-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ES2292611T3 (es) * 2000-08-08 2008-03-16 Evergreen Packaging International B.V. Procedimiento para la activacion de componentes secuestradores de oxigeno durante un proceso de llenado de cajas de carton con tapa de pico.
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1325743A4 (en) 2000-10-13 2004-12-15 Chugai Pharmaceutical Co Ltd COMPOSITIONS TO IMPROVE FAT METABOLISM
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
JP2008531726A (ja) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション 改良されたガシクリジン製剤
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
SI1928405T1 (sl) 2005-09-28 2014-12-31 Auris Medical Ag Farmacevtski sestavki za zdravljenje motenj notranjega ušesa
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
WO2008011125A2 (en) * 2006-07-20 2008-01-24 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
CA2659330A1 (en) * 2006-07-31 2008-02-07 Neurosystec Corporation Nanoparticle drug formulations
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
ES2596262T3 (es) * 2007-09-12 2017-01-05 Merz Pharma Gmbh & Co. Kgaa Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US20150044200A1 (en) 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
EP0759295A1 (de) 1997-02-26
DE19528388A1 (de) 1997-02-06
KR19990036073A (ko) 1999-05-25
KR100393296B1 (ko) 2003-11-17
MX9800925A (es) 1998-10-31
DK0759295T3 (da) 1999-01-25
ES2116801T3 (es) 1998-07-16
JP3568039B2 (ja) 2004-09-22
BR9609950A (pt) 1999-06-29
US6066652A (en) 2000-05-23
AU6788296A (en) 1997-02-26
CN1142775C (zh) 2004-03-24
EP0759295B1 (de) 1998-03-04
DE19680619D2 (de) 1998-10-29
EP0834310A1 (de) 1998-04-08
DE59600105D1 (de) 1998-04-09
CN1194581A (zh) 1998-09-30
JP2000515486A (ja) 2000-11-21
AU719018B2 (en) 2000-05-04
ATE163545T1 (de) 1998-03-15
IL123142A0 (en) 1998-09-24
WO1997004762A1 (de) 1997-02-13
PL324795A1 (en) 1998-06-22

Similar Documents

Publication Publication Date Title
AU719018B2 (en) Use of adamantane derivatives for treating diseases of the inner ear
Melding et al. The treatment of tinnitus with oral anticonvulsants
US6911475B1 (en) Use of nicotine or its derivatives in a drug for treating neurological disease, in particular Parkinson's disease
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US6903100B2 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
US20020010201A1 (en) Method for treating restless leg syndrome using pramipexole and clonidine
Lin et al. Pharmacology of balance and dizziness
US20120035207A1 (en) Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome
SK281982B6 (sk) Použitie zlúčenín gabapentínu na výrobu liečiva
EP1020189A1 (en) Prophylactic or therapeutic agent for amnesia
CA2228393C (en) Use of adamantane derivatives for treating diseases of the inner ear
Monti et al. The selective histamine H1-receptor agonist 2-(3-trifluoromethylphenyl) histamine increases waking in the rat
Pisania et al. Single dose pharmacokinetics of carbamazepine-10, 11-epoxide in patients on lamotrigine monotherapy
Ryan et al. Immunological damage to the inner ear: current and future therapeutic strategies
Kempster et al. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations
Sitges et al. Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing
D'aleo et al. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms
MXPA98000925A (es) Uso de derivados de adamantano para tratar enfermedades del oido interno
US3642994A (en) Therapeutic process using melatonin
Ahlenius et al. Central 5-HT and the respiratory response to acoustic stimulation in awake rats: effects of PCPA, 5-HTP and 8-OH-DPAT
Weksler et al. Lidocaine pretreatment effectively decreases the incidence of hiccups during methohexitone administration for dilatation and curettage
Gates Innovar treatment for Meniere's disease
Goetting Catamenial exacerbation of action myoclonus: successful treatment with acetazolamide.
Broncel et al. Bisoprolol in the treatment of hypertension in the elderly
Sataloff et al. Very high-dose streptomycin labyrinthectomy

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees